Revolutionizing Pain Management with PRECISION PUMP MODULATORS
DOL-001 introduces a novel class of precision drugs, Precision Pump Modulators, modulating the ion pump rather than ion channels. By down-regulating FXYD2, a key regulator of neuronal hyperexcitability, DOL-001 reduces pathological nerve activity while preserving normal sensory function.
Our Lipid-ASO modality drives efficient delivery to peripheral nociceptors in the dorsal root ganglion, with high specificity and no CNS exposure, avoiding the side effects that have limited previous approaches. This groundbreaking technology provides a powerful, non-opioid alternative to current treatments, addressing one of the most pressing challenges in pain care.
We are advancing DOL-001 as a non-opioid solution for severe chronic pain, with our first clinical application focused on severe cancer pain.
Why We Must Innovate in Pain Management
Severe pain disrupts every aspect of life, from daily activities to social connections. Current treatments, especially opioids, have serious drawbacks like addiction, cognitive issues, and reduced effectiveness over time, leaving patients with few options and contributing to 600,000 deaths annually.
This is especially urgent in end-of-life care, where pain deeply affects dignity and quality of life. Our mission is to create innovative solutions to address this critical need and change the future of pain management.
Precise targeting
FXYD2 is highly specific to the DRG, ensuring targeted and precise therapeutic action.
Less side effects
L-ASO technology offers greater specificity than small molecules, resulting in fewer side effects and no risk of dependency.
Outstanding preclinical Results
Validated efficacy across multiple models, including SNL, inflammatory, and Oxaliplatin-induced pain models.
How it works: 3 key steps
New Target : FXYD2
Our research is centered on the Fxyd2 gene, which encodes the γ subunit of the Na,K-ATPase pump.
With a highly restricted expression profile, FXYD2 is prominently expressed in kidneys and specific subsets of somatosensory neurons in the dorsal root ganglia (DRG) of humans.
FXYD2 is a key protein involved in regulating neuronal hyperexcitability.
New Modality : L-ASO
The unparalleled efficacy of our L-ASO (Lipid-Antisense Oligonucleotide) technology lies in its unique and proprietary conformation.
This innovative structure enables precise targeting of nociceptive signaling pathways, ensuring exceptional effectiveness in managing severe and intractable pain.
Unlike traditional ASO approaches, our L-ASO's novel design enhances cellular uptake and bioavailability while minimizing side effects, making it a truly disruptive solution.
Our analyses, based on NMR and circular dichroism, demonstrate that the conjugate induces a specific folding conformation.
Applications for Severe Pain Management
Severe cancer pain affects a significant proportion of cancer patients and is a leading driver of treatment discontinuation. Despite its severity, it remains one of the most difficult pain conditions to treat. Opioids are still the standard of care, yet their efficacy is partial, and prolonged use carries well-documented risks of dependence and tolerance. No durable non-opioid alternative currently exists, and the unmet medical need is substantial.
Our Precision Pump Modulator (PPM) offers a non-opioid solution for severe cancer pain and a game-changing long-lasting effect.
Key Elements Strengthening Our Project
TARGET
Technology
ROUTES OF ADMINISTRATION
of DOL-001
Timeline
Discovery of Fxyd2 expression in the peripheral nervous system (Plos One)
Discovery of FXYD2's role in sustaining neuropathic and chronic inflammatory pain (Scientific Reports publication)
Development of a therapeutic strategy based on L-ASO technology
Optimization of the IV administration route (JCI Insight)
Dolinnov launches with successful first funding round
Initiation of safety studies, dose ranging, and manufacturing scale-up.
Focusing on translational studies + regulatory toxicology
Initiate a clinical trial as soon as possible.
Pipeline
We have demonstrated that DOL001, powered by our proprietary L-ASO technology, effectively addresses both neuropathic and inflammatory pain, showcasing its versatility and potential across multiple pain indications.
Product
Research
Preclinical
Phase 1
Phase 2
Phase 3
DOL-001
Severe cancer pain
DOL-001
Rare disorders
DOL-002
Non disclosed
Publications
Below, you will find the three principal publications highlighting the scientific work and advancements related to FXYD2.
